US4018918A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Topical clindamycin preparations
Assignee: Pharmacia and Upjohn Co
•
Filing: 1976-03-19
•
Granted: 1977-04-19
•
Expires: 1996-03-19
Abstract
Abstract Disclosed is an anti-inflammatory compound, 6α,9α-di-fluoro-11β,17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate, and topical pharmaceutical formulations which include antimicrobial agents.
Inventors
- 👤 Donald E. Ayer
- 👤 Carl A. Schlagel
- 👤 Gordon L. Flynn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 11:54
CPC Classifications
C; C07; C07J; C07J5/00; C07J5/0046; C07J5/0061; C07J5/0069; C07J5/0076; A; A61; A61K; A61K31/00; A61K31/56; A61K31/57; A61K31/70; A61K8/00; A61K8/18; A61K8/30; A61K8/60; A61K8/602; A61K8/63; A61Q; A61Q17/00; A61Q17/04
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
48 words
A therapeutic composition for topical or local application for treatment of affected dermatosis comprising an anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate, an antibacterial therapeutic amount of clindamycin or pharmaceutically acceptable salt or ester thereof and an antifungal therapeutic amount of chloroxine in association with a pharmaceutical carrier.
Claim 2
Dependent Claim
48 words
A therapeutic composition for topical or local application for treatment of affected dermatosis comprising an anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate, an antibacterial therapeutic amount of clindamycin or pharmaceutically acceptable salt or ester thereof and an antifungal therapeutic amount of chloroxine in association with a pharmaceutical carrier.
Claim 3
Dependent Claim
66 words
A therapeutic composition according to claim 1, where the anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate is from about 0.01 percent to about 0.1 percent, where the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is from about 0.5 percent to about 2 percent and where the antifungal therapeutic amount of chloroxine is from about 1 percent to about 2 percent.
Claim 4
Dependent Claim
51 words
A therapeutic composition according to claim 1 where the anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate is 0.05 percent, where the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is 1 percent and where the antifungal therapeutic amount of chloroxine is not more than 1.5 percent.
Claim 5
Dependent Claim
11 words
A therapeutic composition according to claim 3 which is a cream.
Claim 6
Dependent Claim
11 words
The therapeutic composition according to claim 3 which is an ointment.
Claim 7
Dependent Claim
43 words
A therapeutic composition for topical or local application for treatment of infected dermatoses comprising an anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate and an antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutical carrier.
Claim 8
Dependent Claim
43 words
A therapeutic composition for topical or local application for treatment of infected dermatoses comprising an anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate and an antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof in association with a pharmaceutical carrier.
Claim 9
Dependent Claim
50 words
A therapeutic composition according to claim 6 where the anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α,21-trihydroxy-16β-methylpregna-1,4-diene 3,20-dione 17,21-diacetate is from about 0.01 percent to about 0.1 percent and the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is from about 0.5 percent to about 2 percent.
Claim 10
Dependent Claim
37 words
A therapeutic composition according to claim 7 where the anti-inflammatory therapeutic amount of 6α,9α-difluoro-11β, 17α-21-trihydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-diacetate if 0.05 percent and the antibacterial therapeutic amount of clindamycin or a pharmaceutically acceptable salt or ester thereof is 1 percent.
Claim 11
Dependent Claim
11 words
A therapeutic composition according to claim 8, which is a cream.
Claim 12
Dependent Claim
11 words
A therapeutic composition according to claim 8, which is an ointment.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-04-18 | 1980-10-18 | 1981-04-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-04-18 | 1984-10-18 | 1985-04-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-04-18 | 1988-10-18 | 1989-04-19 | $7700.00 | Window Closed / Lapsed |